Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at Needham & Company LLC in a research report issued on Monday,Benzinga reports. They presently have a $33.00 price objective on the stock. Needham & Company LLC's price objective suggests a potential upside of 185.47% from the company's current price.
DAWN has been the topic of several other research reports. TD Cowen upgraded Day One Biopharmaceuticals to a "strong-buy" rating in a research note on Monday, November 4th. Bank of America reduced their price target on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a "buy" rating on the stock in a research note on Tuesday, January 7th. Finally, HC Wainwright reiterated a "buy" rating and set a $40.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $35.86.
Check Out Our Latest Analysis on DAWN
Day One Biopharmaceuticals Stock Performance
Shares of NASDAQ DAWN traded down $0.24 during mid-day trading on Monday, reaching $11.56. The company had a trading volume of 2,334,630 shares, compared to its average volume of 1,022,247. Day One Biopharmaceuticals has a one year low of $11.52 and a one year high of $18.07. The business's 50-day simple moving average is $13.37 and its 200 day simple moving average is $13.95. The firm has a market cap of $1.17 billion, a price-to-earnings ratio of -11.22 and a beta of -1.51.
Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last released its earnings results on Wednesday, October 30th. The company reported $0.38 EPS for the quarter, beating the consensus estimate of ($0.20) by $0.58. The firm had revenue of $93.76 million during the quarter, compared to the consensus estimate of $15.05 million. During the same period in the prior year, the business earned ($0.54) earnings per share. On average, sell-side analysts anticipate that Day One Biopharmaceuticals will post -0.88 EPS for the current year.
Insider Transactions at Day One Biopharmaceuticals
In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 11,245 shares of the firm's stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $16.03, for a total transaction of $180,257.35. Following the completion of the transaction, the insider now owns 1,085,790 shares in the company, valued at approximately $17,405,213.70. This trade represents a 1.03 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last 90 days, insiders have sold 51,745 shares of company stock worth $748,567. Company insiders own 8.40% of the company's stock.
Institutional Trading of Day One Biopharmaceuticals
Institutional investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. increased its holdings in Day One Biopharmaceuticals by 38.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company's stock worth $51,000 after purchasing an additional 1,002 shares in the last quarter. Quest Partners LLC boosted its position in shares of Day One Biopharmaceuticals by 9,238.6% during the 3rd quarter. Quest Partners LLC now owns 7,751 shares of the company's stock worth $108,000 after purchasing an additional 7,668 shares in the last quarter. Point72 DIFC Ltd bought a new position in Day One Biopharmaceuticals in the second quarter worth approximately $124,000. Hsbc Holdings PLC bought a new position in Day One Biopharmaceuticals in the second quarter worth approximately $163,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in Day One Biopharmaceuticals in the 3rd quarter valued at $174,000. Institutional investors own 87.95% of the company's stock.
About Day One Biopharmaceuticals
(
Get Free Report)
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.
Featured Stories
Before you consider Day One Biopharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Day One Biopharmaceuticals wasn't on the list.
While Day One Biopharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
